OVID logo

OVID Ovid Therapeutics Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$2.20
-0.14 (-5.98%)

Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotrans…

Market Cap: $415.21Mwww.ovidrx.com

Price

No data yet.

Social Signal Score

50
5d
—
30d
50
2 mentions
—
60d
50
2 mentions
—
90d
50
2 mentions
—
news: 2

Analyst Ratings

14 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 3Sell 0Strong Sell 0
Avg price target$6.25+184.1%
Low $5Median $6High $8
Current Consensus

Revenue

$0.00
$0.00$69.46M$138.92M$208.38M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.48
$-0.60–$-0.40
8 analysts
FY2026
$-0.40
$-0.43–$-0.37
10 analysts
FY2027
$-0.44
$-0.76–$-0.30
10 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Margaret Alexander
Sector
Healthcare
Industry
Biotechnology
Employees
23
Beta
0.24
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
8.26
www.ovidrx.com